EL7.AI
StocksMedium•18 November 2026•
4 min read

M1 Kliniken Raises Target EBIT Margin to 25% and Plans Prime Standard Listing in 2027

Key Facts

1M1 Kliniken raised its target for the Beauty segment’s sustainable EBIT margin by 2029 from at least 20% to at least 25%.
2The company kept its Beauty revenue target of €200 million to €300 million by 2029 unchanged.
3Beauty revenue rose 11% to €56.9 million in the first half of 2026, compared with €51.2 million in the corresponding period of 2025.
4Beauty segment EBIT increased 23.8% to €18.6 million in the first half of 2026, compared with €15.0 million in the first half of 2025.

In its statement dated November 17, M1 Kliniken said its management board, with the approval of the supervisory board, had decided to prepare the transfer of the company’s shares from the open market, Basic Board, to the regulated market, Prime Standard, on the Frankfurt Stock Exchange. The planned move coincides with the company raising its target for a sustainable EBIT margin in the Beauty segment to at least 25% by 2029, from at least 20% previously. The company said the new margin target applies to the Beauty segment, while its revenue target remains unchanged. The announcement thus combines a market step aimed at meeting Prime Standard listing requirements with a higher profitability target for the segment. According to the company, the planned admission date during 2027 remains subject to meeting the admission requirements.

The higher margin target represents an increase of 5 percentage points in the minimum level the company is targeting for the Beauty segment by 2029. M1 Kliniken, by contrast, did not raise its revenue target, keeping the range at €200 million to €300 million for the same period. This puts the two targets on parallel tracks: segment revenue within the announced range and a sustainable EBIT margin of at least 25%. The profitability comparison is with the previous target of at least 20%, while the revenue range is unchanged from the level the company had announced earlier. The announcement did not specify, in the information available, an operational reason for raising the margin target.

The first-half 2026 results provide a numerical backdrop to the Beauty segment’s performance ahead of the announcement of the higher target. Segment revenue rose 11% to €56.9 million, compared with €51.2 million in the first half of 2025, according to company data. Segment EBIT increased 23.8% to €18.6 million, from €15.0 million in the year-earlier period. The EBIT margin in the first half was also 32.7%, against 29.4% in the first half of 2025. These figures show an annual improvement in the segment’s revenue and operating profitability, but they cover a half-year period, while the announcement targets a sustainable margin by 2029.

At group level, M1 Kliniken recorded revenue of €76.6 million and EBIT of €15.6 million in the first half of 2026. Group revenue was €183.5 million in the first half of 2025, while EBIT then stood at €18.0 million, according to company data. The decline in group revenue compared with the previous period followed the sale of the HAEMATO Pharm business, according to the context in the company’s announcement. The comparison highlights the different trajectories of the segment and the group as a whole: Beauty revenue rose in the first half, while group revenue fell from the year-earlier period. Beauty’s 2029 targets therefore relate to the segment’s performance and do not by themselves mean total group revenue is moving in the same direction.

The company had linked its improved 2025 results to operational efficiency gains and targeted expansion of medical capacity. M1 Kliniken said the development “was based in particular on efficiency gains in operational processes and the targeted expansion of medical capacity.” This statement provides context for what the company said about its 2025 results; it does not identify these factors as the reason for raising the Beauty margin target in the November 17 announcement. The direct comparison available for the segment remains the growth in revenue, EBIT and margin in the first half of 2026 against the same period in 2025. The revenue and margin targets, meanwhile, extend to 2029, a different time horizon from the first-half results.

The next step on the listing front is to prepare the move from Basic Board to Prime Standard, with a view to securing admission during 2027. The company said the planned date is subject to meeting the admission requirements, and that announcing its preparations does not by itself mean the transfer has been completed. In parallel, the Beauty targets through 2029 remain revenue of €200 million to €300 million and a sustainable EBIT margin of at least 25%. The announced timetable means the listing process has a nearer planned date, while the segment’s financial targets extend to the end of their target period. The announcement provided no further details on the timing of the listing process stages or new interim indicators for the segment.